CD47 and myeloid neoplasm: Magrolimab is an anti-CD47 monoclonal antibody that is currently under investigation in clinical trials in refractory indolent B-cell malignancies (NCT04599634) and myeloid malignancies (NCT04778410) and in a phase 2 clinical trial in patients with solid tumors, including metastatic urothelial cancer (NCT04827576).